Fate Therapeutics, Inc.
FATE
$1.08
$0.087.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -46.92% | -31.23% | 105.85% | -78.55% | -87.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.92% | -31.23% | 105.85% | -78.55% | -87.34% |
| Cost of Revenue | -14.13% | -3.76% | -30.34% | -43.28% | -61.21% |
| Gross Profit | 8.25% | -0.71% | 37.87% | 19.35% | 38.41% |
| SG&A Expenses | -26.73% | -13.99% | -12.75% | -6.42% | 8.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.43% | -10.45% | -9.29% | -17.66% | -32.91% |
| Operating Income | 18.62% | 9.14% | 12.79% | -2.64% | 4.96% |
| Income Before Tax | 12.42% | 2.39% | 7.46% | -15.74% | -2.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.42% | 2.39% | 7.46% | -15.74% | -2.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.42% | 2.39% | 7.46% | -15.74% | -2.92% |
| EBIT | 18.62% | 9.14% | 12.79% | -2.64% | 4.96% |
| EBITDA | 18.15% | 8.35% | 13.29% | -2.52% | 5.86% |
| EPS Basic | 20.26% | 14.93% | 22.13% | -0.92% | 6.37% |
| Normalized Basic EPS | 30.01% | 24.54% | 32.21% | 12.14% | 6.03% |
| EPS Diluted | 20.26% | 14.93% | 22.13% | -0.92% | 6.40% |
| Normalized Diluted EPS | 30.01% | 24.54% | 32.21% | 12.14% | 6.03% |
| Average Basic Shares Outstanding | 8.91% | 13.64% | 18.84% | 15.37% | 10.89% |
| Average Diluted Shares Outstanding | 8.91% | 13.64% | 18.84% | 15.37% | 10.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |